GEMINI

About Revelation Biosciences

Revelation Biosciences is developing GEMINI, a first-in-class innate immune system modulator designed to rebalance inflammation and prevent tissue damage. The company has generated positive early clinical data in preventing Acute Kidney Injury (AKI) and is exploring its platform's potential in broad inflammatory and infectious conditions. Its strategy hinges on clinically validating its 'innate immune conditioning' hypothesis in surgical settings as a pathway to addressing larger, dysregulated inflammatory markets. As a pre-revenue, NASDAQ-listed entity, its near-term value catalysts are tied to clinical trial readouts and strategic partnership development.

About Revelation Biosciences

Revelation Biosciences is developing GEMINI, a first-in-class innate immune system modulator designed to rebalance inflammation and prevent tissue damage. The company has generated positive early clinical data in preventing Acute Kidney Injury (AKI) and is exploring its platform's potential in broad inflammatory and infectious conditions. Its strategy hinges on clinically validating its 'innate immune conditioning' hypothesis in surgical settings as a pathway to addressing larger, dysregulated inflammatory markets. As a pre-revenue, NASDAQ-listed entity, its near-term value catalysts are tied to clinical trial readouts and strategic partnership development.

Therapeutic Areas